Swapping from Mounjaro to Wegovy: What the Evidence and Real Reviews Tell You

What the head-to-head trial found — and why it matters for switching decisions

The most useful place to start is the evidence generated when the two medicines were tested directly against each other. The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, randomised adults with obesity and no diabetes to either tirzepatide (Mounjaro) or semaglutide 2.4mg (Wegovy) over 72 weeks. On average, tirzepatide produced greater weight reduction across the trial period. That finding was reflected in NICE's technology appraisal of tirzepatide (TA1026), which noted that indirect comparisons favoured tirzepatide when weighed against semaglutide data.

What does that mean for someone considering a swap? It means the population-level average runs in one direction, but averages hide a lot. Some people respond strongly to semaglutide and less well to tirzepatide; others find the gastrointestinal side-effect profile of one medicine harder to tolerate than the other. A headline trial result does not tell you which medicine will suit your physiology, your other health conditions, or the medications you take alongside it.

For completeness: NICE's recommendation for semaglutide (TA875) covers Wegovy specifically, including its NHS eligibility criteria. The gap between the two medicines has also narrowed with the approval of the higher 7.2mg semaglutide dose, which trials reported producing around 20.7% average weight loss over 72 weeks, approaching tirzepatide's 15mg results. Specific dose availability is always confirmed at consultation rather than assumed.

What people switching describe: patterns in the accounts

A question our prescribers hear most weeks is some version of: "I've read that people who switched from Mounjaro to Wegovy (or the other direction) felt very different, is that normal?" It is a reasonable thing to ask. The two medicines use distinct receptor pathways: tirzepatide activates both GIP and GLP-1 receptors, while semaglutide acts on GLP-1 alone. That mechanistic difference can translate into a different lived experience, even though both are once-weekly injections with broadly similar side-effect profiles.

Accounts from people who have switched tend to cluster around a few recurring themes. Some report that the GI side effects they experienced on one medicine were noticeably less pronounced on the other. Others notice that appetite suppression feels different in quality, not necessarily stronger or weaker, but sitting differently through the day. A smaller group reports little subjective difference at all between the two. If you want to read first-hand experiences in more detail, our collection of Mounjaro to Wegovy reviews brings together accounts from people who have made this switch. None of this is surprising given the distinct mechanisms involved, and none of it is predictable in advance for any individual.

Switching in the direction covered on the semaglutide to tirzepatide page tends to raise different questions from the reverse direction, the Mounjaro to Wegovy switch page goes into the process in more detail. The key point here is that anecdotal accounts, however consistent, are not a substitute for a prescriber reviewing whether the switch is clinically appropriate for you specifically.

A side-by-side look at the two medicines

The table below captures the main factual differences between Mounjaro and Wegovy as licensed for weight management in the UK. It is not a recommendation either way.

Sources: SURMOUNT-1, NEJM; STEP 1, NEJM; SURMOUNT-5, NEJM 2025; NICE TA1026; NICE TA875.

How a switch is handled clinically, and what it is not

Switching between these two medicines is not simply a matter of stopping one pen and starting another. A prescriber needs to review the reason for switching, your current dose, how long you have been on treatment, your weight trajectory, any side effects you have experienced, and whether the new medicine is appropriate given your full medical picture. That is not bureaucracy for its own sake; it is the clinical assessment that makes the switch safe.

For people already on treatment elsewhere, reviews from patients who have gone through this change from Mounjaro to Wegovy often mention that the process felt smoother when a prescriber was actively involved from the start, managing the dose-start point rather than defaulting to the lowest dose unnecessarily, and flagging any interactions with other medications in advance. If you are ready to take that step, our guide to swapping from Mounjaro to Wegovy explains what to expect before you begin. The Wegovy vs Mounjaro comparison covers the broader landscape if you are still weighing up the two medicines from the beginning.

Neither Mounjaro nor Wegovy is right for everyone. Pregnancy, breastfeeding and plans to conceive are contraindications; these medicines are not licensed for use under 18. Certain conditions (including a history of pancreatitis or medullary thyroid carcinoma) require careful prescriber discussion before either medicine is used. The NHS patient information for tirzepatide and the equivalent semaglutide page set out the full contraindication picture in plain language.

Which medicine suits you is a clinical decision our prescribers make with you, not something that can be settled by trial averages or other people's accounts alone. If you are ready to have that conversation, you can check your eligibility and start your free consultation today.